Suppr超能文献

人源甲酰肽受体 3 的生物工程化 G 蛋白偶联受体的生产。

Production of a bioengineered G-protein coupled receptor of human formyl peptide receptor 3.

机构信息

Center for Bioengineering and Biotechnology, China University of Petroleum (East China), Qingdao, Shandong, China.

出版信息

PLoS One. 2011;6(8):e23076. doi: 10.1371/journal.pone.0023076. Epub 2011 Aug 11.

Abstract

G-protein coupled receptors (GPCRs) participate in a wide range of vital regulations of our physiological actions. They are also of pharmaceutical importance and have become many therapeutic targets for a number of disorders and diseases. Purified GPCR-based approaches including structural study and novel biophysical and biochemical function analyses are increasingly being used in GPCR-directed drug discovery. Before these approaches become routine, however, several hurdles need to be overcome; they include overexpression, solubilization, and purification of large quantities of functional and stable receptors on a regular basis. Here we report milligram production of a human formyl peptide receptor 3 (FPR3). FPR3 comprises a functionally distinct GPCR subfamily that is involved in leukocyte chemotaxis and activation. The bioengineered FPR3 was overexpressed in stable tetracycline-inducible mammalian cell lines (HEK293S). After a systematic detergent screening, fos-choline-14 (FC-14) was selected for subsequent solubilization and purification processes. A two-step purification method, immunoaffinity using anti-rho-tag monoclonal antibody 1D4 and gel filtration, was used to purify the receptors to near homogeneity. Immunofluorescence analysis showed that expressed FPR3 was predominantly displayed on cellular membrane. Secondary structural analysis using circular dichroism showed that the purified FPR3 receptor was correctly folded with >50% α-helix, which is similar to other known GPCR secondary structures. Our method can readily produce milligram quantities of human FPR3, which would facilitate in developing human FPR as therapeutic drug targets.

摘要

G 蛋白偶联受体(GPCRs)参与了我们生理活动的广泛而重要的调节。它们在药物方面也具有重要意义,已成为许多疾病和障碍的多种治疗靶点。包括结构研究和新型生物物理和生化功能分析在内的基于纯化 GPCR 的方法越来越多地被用于 GPCR 导向的药物发现。然而,在这些方法成为常规方法之前,还需要克服几个障碍;它们包括定期大量表达、溶解和纯化功能稳定的受体。在这里,我们报告了毫克级人源形式肽受体 3(FPR3)的生产。FPR3 包含一个功能独特的 GPCR 亚家族,涉及白细胞趋化性和激活。生物工程化的 FPR3 在稳定的四环素诱导的哺乳动物细胞系(HEK293S)中过表达。在进行了系统的去污剂筛选后,选择 fos-choline-14(FC-14)用于随后的溶解和纯化过程。使用抗 rho 标记单克隆抗体 1D4 的免疫亲和层析和凝胶过滤的两步纯化方法,可将受体纯化至接近均一性。免疫荧光分析表明表达的 FPR3 主要显示在细胞膜上。使用圆二色性进行的二级结构分析表明,纯化的 FPR3 受体具有正确折叠的超过 50%的α-螺旋,这与其他已知的 GPCR 二级结构相似。我们的方法可以轻松地生产毫克级的人源 FPR3,这将有助于开发人源 FPR 作为治疗药物靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21d3/3154916/081000fd549f/pone.0023076.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验